Quote mark

LDC backed our business in 2021, and supported us when it came to the acquisitions of MedDX and Shuttlepac. Looking ahead, we are really excited about the opportunity in the US, where a number of major pharmaceutical companies are interested in using our automation capability.”

Chris Tagg, Chief Strategy Officer

Christian Bruning, Partner, LDC, added, “RDi has a unique proposition and is well positioned to take advantage of the phenomenal interest in healthcare screening, testing and monitoring, both in the US and globally. RDi has made its name with screening kits, including bowel cancer detection kits, since 2008, and is now successfully expanding this to other types of health screening as early-detection continues to rise up the agenda of individuals, companies and governments.”

“The business is also highly focused on sustainability, and on reducing the use of plastics by minimizing the size of its kits, components and packaging. We are proud to support RDi’s ambitious management team in their impressive growth story.”